医疗-牙科用品股票 - Merit Medical (MMSI) 和 Align Technology (ALGN) 是投资者熟悉的医疗-牙科用品股票[1] 投资机会发现 - Zacks Rank 和 Style Scores 系统中的价值类别是发现优质投资机会的最佳途径[2] 公司评级 - MMSI 的 Zacks Rank 为 2 (买入)，ALGN 的 Zacks Rank 为 3 (持有)[3] 价值投资 - 价值投资者使用多种传统的指标来寻找被低估的公司[4]

Shares of Align Technology (ALGN 4.87%) soared in early trading on Thursday, up as much as 15%. This initial positive reaction came after the company reported financial results for the fourth quarter of 2023. However, Align Technology stock surrendered those early gains and was up less than 1% as of 11:30 a.m. ET. Here's what's going on. Ending 2023 on a high note Align Technology provides teeth-straightening services through its Invisalign clear aligners and through its iTero mouth-scanning devices. In Q4, ...

Align Technology, Inc. (ALGN) delivered fourth-quarter fiscal 2023 adjusted earnings per share (EPS) of $2.42, up 39.9% from the year-ago earnings. The reported figure topped the Zacks Consensus Estimate by 11%. GAAP EPS for the quarter was $1.64 compared with 54 cents in the same period last year. Full-year adjusted EPS was $8.61, an increase of 11% from the year-ago period. The same surpassed the Zacks Consensus Estimate by 3%. Revenues Revenues increased 6.1% year over year to $956.7 million in the quart ...

公司财务信息 - 公司2023财年总收入为386.23亿美元，同比增长3.4%[26] - 2023财年非GAAP运营利润率超过21%[24] - Q4总收入同比增长6.1%，达到95.67亿美元[27] - Q4系统和服务收入同比增长5.8%，达到17.48亿美元[27] - Q4清晰矫正器收入同比增长2.9%，达到78.19亿美元[27] - Q4清晰矫正器出货量同比增长6.9%[27] - 2023财年非病例清晰矫正器收入同比增长14.0%达到2.869亿美元[28] - 2023年第四季度，非病例无托清晰矫治器收入同比增长13.3%[31] - 2023年全年，Invisalign DSP补偿病例发货量同比增长85%至73,000例[34] - 2023年全年，青少年和儿童使用Invisalign系统治疗人数达到4.7百万[36] - 2023年全年，Invisalign品牌消费者营销产生了全球57.9亿网站访问量[38] - 2023年全年，GAAP净收入为3,862,260千美元，较2022年的3,734,635千美元增长了3.4%[71] 公司产品和技术 - 公司推出了iTero Lumina™口腔扫描仪，具有更广阔的扫描范围和更高的准确性[15] - Invisalign® Palatal Expander system获得美国FDA 510(k)清关，适用于广泛的患者[16] - ClinCheck® Smile Video是下一代面部可视化工具，预计将在北美和EMEA地区推出[17] - Align Technology在2023年获得了美国专利，涵盖了革新牙科和数字牙科领域的技术[19] - 公司已经售出超过10万台iTero扫描仪，每年进行超过500万次修复扫描[42] - Invisalign®案例的口腔数字扫描提交量在Q4'23达到了7.055亿美元，同比增长95.1%[43] - exocad推出了DentalCAD3.2 Elefsina软件，拥有60多项新功能，提高了自动化和速度[45] 公司展望和策略 - 公司预计2024年第一季度全球营收将在9.6亿至9.8亿美元之间，略高于2023年第四季度[64] - 预计2024年总收入将比2023年增长中单位数位数[65] - 预计2024年透明矫正器和系统服务收入将与2024年总收入大致相同的范围内同比增长[65] - 预计2024年透明矫正器平均售价将同比略有上升[65] - Align Technology Inc.对2024年的创新和增长驱动力感到更加兴奋[67] - Align Technology Inc.引入了iTeroLumina™，推动了口腔扫描技术的边界[67] - Align Technology Inc.收购了Cubicure，这将帮助创造更可持续和高效的解决方案[67] - Align Technology Inc.推出了IPE，扩大了Invisalign系统的临床适用性[67] - Align Technology Inc.为支持Invisalign医生帮助DTC患者，推出了折扣计划[68]

业绩总结 - 2023财年总收入超出先前预期[13] - Q4总收入同比增长6.1%[14] - 2023财年非案例收入同比增长13.3%[16] - 第四季度总收入为9.567亿美元，环比下降0.4%，同比增长6.1%[29] - Clear Aligners的第四季度收入为7.819亿美元，环比下降1.6%，同比增长6.9%[29] - 第四季度整体毛利率为70%，环比上升0.9个百分点，同比上升1.5个百分点[36] - 第四季度营业利润为1.715亿美元，营业利润率为17.9%，环比上升0.6个百分点，同比上升5.4个百分点[41] - 第四季度每股净收入为1.64美元，环比增长0.06美元，同比增长1.10美元[45] - 2023年12月31日，现金、现金等价物和短期和长期可变现证券为9.808亿美元，环比减少3.212亿美元，同比减少0.608亿美元[46] - 第四季度经营活动现金流为4690万美元[47] - 预计2024年第一季度全球营收范围为9.6亿至9.8亿美元，略高于2023年第四季度[48] - 预计2024财年总营收同比增长中等个位数[49] 用户数据 - 2023财年Invisalign Clear Aligner出货量同比增长8%[19] - 美国FDA批准Invisalign Palatal Expander System在美国商业上市[20] - 推出ClinCheck smile video，预计在北美和EMEA地区推出[23] - 推出iTero Lumina inter-oral scanner，提供更快的扫描速度和更高的准确性[25] 未来展望 - 公司预计2024年的市场增长率为中单位数位[61] - 预计第一季度的运营利润率会有所下降，但随着年度的推进会逐步提升[65] - 公司计划通过增加销量来提高利润率[70] - 公司对2024年的经济环境更为稳定，预计成年人和青少年的销量将持续增长[91] 新产品和新技术研发 - 公司推出了新的产品线，预计2024年将会是新技术的起步阶段[78] - Lumina和IPE产品将在未来几个季度逐步推出，但需等待全球的监管批准[88] - 公司对3D打印技术的成本优势和规模效应充满信心，预计将在未来几年逐步体现[82] 市场扩张和并购 - 2023年9月的财政年度，中国市场创下iPhone收入纪录为967.7亿美元[110] - 公司对当前宏观环境持稳定态度，认为新产品如Lumina和IPE有助于在当前环境下增长[81] - 公司对2024年的增长前景持乐观态度，认为稳定的经济环境和新产品的推出将有助于公司发挥更大的作用[114][115]

For the quarter ended December 2023, Align Technology (ALGN) reported revenue of $956.73 million, up 6.1% over the same period last year. EPS came in at $2.42, compared to $1.73 in the year-ago quarter. The reported revenue represents a surprise of +3.03% over the Zacks Consensus Estimate of $928.57 million. With the consensus EPS estimate being $2.18, the EPS surprise was +11.01%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to de ...

Shares of Align Technology Inc. ALGN, +0.97% jumped 14.1% after hours on Wednesday after the company, best known for its Invisalign teeth-alignment system, forecast first-quarter and full-year sales that were above expectations. Align said it expected first-quarter sales of $960 million to $980 million, above the FactSet consensus forecast for $947 million. For the full year, the company expected sales to be “up mid-single digits” year over year, compared with FactSet expectations for around 4% growth. For ...

公司介绍 - Align Technology, Inc.是一家全球领先的医疗器械公司，设计、制造和销售Invisalign®系统的透明矫正器、iTero™口腔内扫描仪和exocad™数字正畸和修复牙科CAD/CAM软件[1] - Align Technology已经在研发上投入了约20亿美元，持续近27年，通过在3D计算机建模、材料科学和生物力学方面的创新，推动数字牙科领域的发展，帮助医生改善患者的笑容和生活[6] 专利信息 - Align Technology首次被列入知识产权所有者协会年度报告的前300家获得美国专利的组织名单，2023年排名第270位，获得158项美国专利，较2022年增长36%[1] - Align Technology的专利涵盖了革新正畸学和数字牙科领域的技术，包括透明矫正器、口腔内扫描仪、直接3D打印的正畸器械、修复CAD/CAM软件和治疗规划中的人工智能等方面[3] 产品创新 - iTero™ Lumina口腔内扫描仪是下一代数字扫描技术，提供了更广阔的捕捉范围、更高的准确性和更大的捕捉距离，为用户和患者提供了更顺畅的扫描体验[3] - Invisalign® Palatal Expanders是Align的首款直接3D打印的正畸器械，提供了一种安全、舒适和临床有效的替代方案，不需要每天在口腔内手动旋转螺丝来实现扩张[5]

Analysts on Wall Street project that Align Technology (ALGN) will announce quarterly earnings of $2.17 per share in its forthcoming report, representing an increase of 25.4% year over year. Revenues are projected to reach $928.43 million, increasing 3% from the same quarter last year. Over the last 30 days, there has been an upward revision of 1.2% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial fo ...

Align Technology’s (ALGN) macroeconomic issues and currency headwinds continue to dent growth. The stock carries a Zacks Rank #4 (Sell). Align Technology is suffering from the ongoing industry-wide trend of staffing shortages and supply chain- related hazards. Deteriorating international trade, with global inflationary pressure leading to a tough situation related to raw material and labor costs, as well as freight charges and rising interest rates, all have put the dental treatment space (which is highly e ...